2HRA H&R GmbH & Co. KGaA
H&R GmbH & Co. KGaA engages in the production and sale of chemical-pharmaceutical raw materials and injection molded precision plastic parts worldwide. It operates through three segments: ChemPharm Refining, ChemPharm Sales, and Plastics. The ChemPharm Refining segment offers paraffins, white oils, plasticizers, base oils, lubricants, and other crude-oil based specialty products, as well as bitumen, feedstocks, and bunker fuel. The ChemPharm Sales segment provides paraffins, plasticizers, wax emulsions, and other crude-oil based specialty products. The Plastics segment develops, manufactures, and sells high-precision plastic parts. The company also provides petroleum jellies, cosmetic and pharmaceutical specialties, process oils, and cable fillers, as well as polymers and APP based products for the construction industry. The company was formerly known as H&R AG and changed its name to H&R GmbH & Co. KGaA in August 2016. H&R GmbH & Co. KGaA was founded in 1919 and is headquartered in Salzbergen, Germany.…
Industry Peers
Specialty ChemicalsKey Statistics
About H&R GmbH (ETR: 2HRA)
›
H&R GmbH (ETR: 2HRA) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Specialty Chemicals industry, part of the Basic Materials sector, and reports about 1,722 employees.
The shares were at 6.600 EUR on 19 November 2026, up 39.8% over 52 weeks. Its 52-week range is 3.910 EUR to 7.600 EUR: the price is 13.2% below the high and 68.8% above the low.
At a market capitalisation of 245.66M EUR, it trades at 94.3 times trailing earnings and 10.8 times forward earnings. The median trailing P/E of its 18 largest Specialty Chemicals peers is 34.0, a premium of 177% for 2HRA.
H&R GmbH reports return on equity of -10.3%, an operating margin of 7.6% and revenue up 32.6% year over year.
Its debt exceeds its cash by 162.03M EUR, a debt-to-equity ratio of 0.49. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 8.200 EUR is 24.2% above the current price.